Topic

California

A collection of 414 issues

Arikayce Coverage with UnitedHealthcare in California: Complete Guide to Prior Authorization, Appeals, and Approval Timeline

Answer Box: Getting Arikayce Covered by UnitedHealthcare in California Arikayce requires prior authorization from UnitedHealthcare through OptumRx. To qualify, you must have refractory MAC lung disease with positive cultures after at least 6 months of combination therapy (macrolide + ethambutol + rifamycin). Your fastest path: Have your pulmonologist or infectious disease specialist
5 min read

The Requirements Checklist to Get Natpara (Parathyroid Hormone) Covered by Aetna (CVS Health) in California

Quick Answer: Getting Natpara (parathyroid hormone) covered by Aetna (CVS Health) in California requires prior authorization with strict clinical documentation. You'll need confirmed hypoparathyroidism diagnosis, failed calcium/vitamin D therapy records, and endocrinologist support. Important: Takeda discontinued Natpara manufacturing globally in late 2024, with U.S. supply ending
5 min read

How to Get Jakafi (Ruxolitinib) Covered by Aetna CVS Health in California: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Jakafi Covered by Aetna CVS Health in California Aetna CVS Health requires prior authorization for Jakafi (ruxolitinib) in California. Submit your request at least 2 weeks in advance via the Availity portal with complete documentation: confirmed diagnosis, hydroxyurea failure evidence (if applicable), baseline labs, and prescriber attestation
7 min read

Renewing Signifor LAR (Pasireotide) Coverage with Humana in California: Timeline, Documentation, and Appeals Guide

Answer Box: Renewing Your Signifor LAR Coverage Renewal triggers: Submit 30-45 days before current authorization expires. Key evidence: Updated UFC/IGF-1 labs showing response, recent clinic notes, and prescriber attestation of continued necessity. California advantage: If Humana denies renewal, file an Independent Medical Review (IMR) through DMHC—72% overall success
5 min read

How Long Does It Take to Get Enbrel (etanercept) Approved by UnitedHealthcare in California? Complete Timeline & Milestones

Answer Box: Quick Timeline Overview Getting Enbrel (etanercept) approved by UnitedHealthcare in California typically takes 3-14 days for standard requests, 24-72 hours for urgent cases. The fastest path requires complete documentation upfront: diagnosis, failed DMARD trials, and specialist prescription. Start by having your rheumatologist submit the prior authorization through UnitedHealthcare&
6 min read

Aetna CVS Health Coverage for Besponsa (Inotuzumab Ozogamicin) in California: Medical Necessity Requirements and Appeal Process

Quick Answer: Getting Besponsa Covered by Aetna CVS Health in California Aetna requires prior authorization for Besponsa (inotuzumab ozogamicin) with strict medical necessity criteria: CD22-positive B-cell ALL diagnosis, relapsed/refractory status, and hepatic monitoring plan. Submit PA through CVS Specialty at 1-888-267-3277. If denied, California patients have strong appeal rights
5 min read

How to Get Ilaris (Canakinumab) Covered by Humana in California: Prior Authorization Guide and Appeal Process

Quick Answer: Getting Ilaris (Canakinumab) Covered by Humana in California Humana requires prior authorization for Ilaris (canakinumab) with step therapy documentation and medical necessity justification. If denied, California residents have strong appeal rights through the DMHC Independent Medical Review (IMR) process with a 73% success rate. Start today: Have your
5 min read

How to Get Evrysdi (risdiplam) Covered by Aetna (CVS Health) in California: Prior Authorization, Appeals, and State Protections

Answer Box: Getting Evrysdi Covered in California Getting Evrysdi (risdiplam) covered by Aetna (CVS Health) in California requires prior authorization with genetic confirmation of SMA, baseline motor assessments, and specialist prescription. If denied, California's robust appeal protections give you strong reversal odds—about 68% of specialty drug appeals
6 min read